HYDRONIDONE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C12H11NO2
Molecular Weight	201.2212
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CN(C(=O)C=C1)C2=CC=C(O)C=C2

InChI

InChIKey=NETTXQJYJRFTFS-UHFFFAOYSA-N

InChI=1S/C12H11NO2/c1-9-2-7-12(15)13(8-9)10-3-5-11(14)6-4-10/h2-8,14H,1H3

HIDE SMILES / InChI

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT02499562 | http://www.gnipharma.com/english/rd/product/f351.shtml | https://adisinsight.springer.com/drugs/800020436

F-351 (Hydronidone), a pyridine derivative, is a non-steroidal antiinflammatory drug. It inhibits hepatic stellate cell proliferation and also the TGF-β signaling pathway. Shanghai Genomics is developing F-351 for the treatment of liver fibrosis induced by HBV chronic hepatitis (HBV). For additional indications, F-351 has the potential to be further developed for Non-alcoholic steatohepatitis (NASH) liver disease, Non-alcoholic fatty liver disease (NAFLD) and chronic kidney failure.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Fibroblast growth factor 1 Target ID: Fibroblast growth factor Sources: https://adisinsight.springer.com/drugs/800020436 \| https://www.ncbi.nlm.nih.gov/pubmed/26797810	Inhibitor 8504

PubMed

Title	Date	PubMed
Tolerability and Pharmacokinetics of Hydronidone, an Antifibrotic Agent for Hepatic Fibrosis, after Single and Multiple Doses in Healthy Subjects: an Open-Label, Randomized, Dose-Escalating, First-in-Human Study.	2017-02	26797810
Simultaneous determination of a novel antifibrotic agent and three metabolites in human urine by LC-MS/MS.	2010-09-15	20800557

Patents

Sample Use Guides

In Vivo Use Guide

A randomized, dose-escalating, first-in-human study was conducted in 88 subjects. Five cohorts of 34 subjects received a single dose of hydronidone capsules at 15-120 mg, and two cohorts of 12 subjects received 90 and 120 mg of hydronidone thrice daily for 7 days, and six subjects received 60 mg of hydronidone thrice daily for 28 days to assess the safety and tolerability. In 36 subjects, hydronidone pharmacokinetics were investigated following oral administration of single (30, 60, and 120 mg) and multiple (60 mg, thrice daily) doses of hydronidone.

Route of Administration: Oral

Name

Type

Language

HYDRONIDONE

Common Name

English

F 351

Preferred Name

English

F-351

Code

English

1-(4-HYDROXYPHENYL)-5-METHYLPYRIDIN-2(1H)-ONE

Systematic Name

English

N-(4-HYDROXYPHENYL)-5-METHYL-2-PYRIDONE

Systematic Name

English

Code System Code Type Description

PUBCHEM

11217901